Lefumide 20 Tablet contains Leflunomide 20 mg, a disease-modifying antirheumatic drug (DMARD) primarily indicated for the treatment of active rheumatoid arthritis and psoriatic arthritis. Leflunomide acts by inhibiting dihydroorotate dehydrogenase, an enzyme involved in pyrimidine synthesis, thereby reducing the proliferation of activated lymphocytes responsible for inflammation and joint damage. This immunomodulatory effect helps to alleviate symptoms such as joint pain, swelling, and stiffness, and slows disease progression. Lefumide 20 Tablet is administered orally, typically once daily, with or without food, under medical supervision. Prior to initiation, baseline liver function tests, complete blood counts, and screening for latent infections are recommended due to potential hepatotoxicity, hematologic abnormalities, and immunosuppressive effects. Common adverse reactions include diarrhea, rash, alopecia, and elevated liver enzymes. Caution is advised in patients with pre-existing liver disease, pregnancy, or those receiving concomitant hepatotoxic or immunosuppressive agents. Regular monitoring of liver function and blood counts is essential during therapy. Lefumide 20 Tablet should be used as part of a comprehensive treatment plan, including physical therapy and symptomatic management, to improve patient outcomes in autoimmune arthritis conditions.